Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens
Previous studies have demonstrated that sera from patients with prostate cancer (PCa) contain autoantibodies that react with tumor-associated antigens (TAAs). Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 se...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/827827 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850172265978658816 |
|---|---|
| author | Liping Dai Jitian Li Rosalia Ortega Wei Qian Carlos A. Casiano Jian-Ying Zhang |
| author_facet | Liping Dai Jitian Li Rosalia Ortega Wei Qian Carlos A. Casiano Jian-Ying Zhang |
| author_sort | Liping Dai |
| collection | DOAJ |
| description | Previous studies have demonstrated that sera from patients with prostate cancer (PCa) contain autoantibodies that react with tumor-associated antigens (TAAs). Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls. Autoantibodies to cyclin B1 were detected in 31.0% of sera from randomly selected patients with PCa versus 4.8% in sera with BPH. In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive. The cumulative positive rate of autoantibodies against seven selected TAAs (cyclin B1, survivin, p53, DFS70/LEDGFp75, RalA, MDM2, and NPM1) in PCa reached 80.5%, significantly higher than that in normal control sera. In summary, autoantibody to cyclin B1 might be a potential biomarker for the immunodiagnosis of early stage PCa, especially useful in patients with normal PSA level. This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa. |
| format | Article |
| id | doaj-art-cfda603f68c04776b490bc840036822b |
| institution | OA Journals |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-cfda603f68c04776b490bc840036822b2025-08-20T02:20:07ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/827827827827Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated AntigensLiping Dai0Jitian Li1Rosalia Ortega2Wei Qian3Carlos A. Casiano4Jian-Ying Zhang5Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USADepartment of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USADepartment of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USADepartment of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USACenter for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92354, USADepartment of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USAPrevious studies have demonstrated that sera from patients with prostate cancer (PCa) contain autoantibodies that react with tumor-associated antigens (TAAs). Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls. Autoantibodies to cyclin B1 were detected in 31.0% of sera from randomly selected patients with PCa versus 4.8% in sera with BPH. In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive. The cumulative positive rate of autoantibodies against seven selected TAAs (cyclin B1, survivin, p53, DFS70/LEDGFp75, RalA, MDM2, and NPM1) in PCa reached 80.5%, significantly higher than that in normal control sera. In summary, autoantibody to cyclin B1 might be a potential biomarker for the immunodiagnosis of early stage PCa, especially useful in patients with normal PSA level. This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.http://dx.doi.org/10.1155/2014/827827 |
| spellingShingle | Liping Dai Jitian Li Rosalia Ortega Wei Qian Carlos A. Casiano Jian-Ying Zhang Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens Journal of Immunology Research |
| title | Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens |
| title_full | Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens |
| title_fullStr | Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens |
| title_full_unstemmed | Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens |
| title_short | Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens |
| title_sort | preferential autoimmune response in prostate cancer to cyclin b1 in a panel of tumor associated antigens |
| url | http://dx.doi.org/10.1155/2014/827827 |
| work_keys_str_mv | AT lipingdai preferentialautoimmuneresponseinprostatecancertocyclinb1inapaneloftumorassociatedantigens AT jitianli preferentialautoimmuneresponseinprostatecancertocyclinb1inapaneloftumorassociatedantigens AT rosaliaortega preferentialautoimmuneresponseinprostatecancertocyclinb1inapaneloftumorassociatedantigens AT weiqian preferentialautoimmuneresponseinprostatecancertocyclinb1inapaneloftumorassociatedantigens AT carlosacasiano preferentialautoimmuneresponseinprostatecancertocyclinb1inapaneloftumorassociatedantigens AT jianyingzhang preferentialautoimmuneresponseinprostatecancertocyclinb1inapaneloftumorassociatedantigens |